6.3.2025 16:08:36 CET | Demant A/S |
Forløb af generalforsamling
Selskabsmeddelelse nr. 2025-04
6. marts 2025
Beslutninger på den ordinære generalforsamling
Demant A/S har i dag afholdt ordinær generalforsamling, der blev afholdt fysisk på selskabets adresse, Kongebakken 9, 2765 Smørum.
I sin tale på generalforsamlingen redegjorde bestyrelsens formand, Niels B. Christiansen, for koncernens udvikling i 2024. Beretningen er tilgængelig på www.demant.com. I sin tale sagde formanden blandt andet:
“I 2024 leverede koncernen organisk vækst på 2 % og et driftsresultat før særlige poster på 4,4 milliarder kroner. Det er i overensstemmelse med de forventninger, som vi måtte revidere halvvejs inde i året, hvor vi også gennemførte omkostningsbesparende tiltag for at bevare lønsomheden.
Demant er fuldt ud dedikeret til at fremme global høresundhed, så vi kan hjælpe flere mennesker til at høre bedre. Vi er i en unik position i forhold til at servicere brugere og kunder fra den første screening, test og tilpasning til løbende personlig behandling. Som et af verdens førende høresundhedsselskaber fokuserer på at skabe vækst og levere attraktive finansielle resultater baseret på en stærk og bæredygtig forretningsmodel. Med vores fokus på innovation, kunstig intelligens og service arbejder vi intensivt på at sikre, at vi leverer på vores langsigtede mål for vækst og indtjening, og også for at 2025 bliver et godt år for Demant.”
Alle bestyrelsens forslag blev vedtaget af generalforsamlingen. Dette medførte blandt andet følgende beslutninger:
At selskabets Annual Report 2024 (årsrapport for 2024) blev godkendt, og at hele årets overskud, DKK 1.658 mio., overføres til selskabets reserver.
At Remuneration Report 2024 (vederlagsrapporten for 2024) blev godkendt.
At bestyrelseshonoraret forbliver det samme som i 2024.
At Niels B. Christiansen, Niels Jacobsen, Sisse Fjelsted Rasmussen og Kristian Villumsen blev genvalgt som bestyrelsesmedlemmer. Derudover blev Katrin Pucknat valgt som nyt medlem af bestyrelsen.
At selskabets revisionsfirma, PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (PwC), blev genvalgt, og at PwC’s opgaver tillige vil omfatte afgivelse af erklæring med begrænset sikkerhed om bæredygtighedsrapportering i ledelsesberetningen.
At selskabets aktiekapital nedsættes med nominelt DKK 1.459.025,80 svarende til selskabets beholdning af egne aktier pr. 4. februar 2025, fraregnet aktier til dækning af ledende medarbejderes og direktionens aktiebaserede fastholdelsesprogram. Selskabets beholdning af egne aktier er for størstedelens vedkommende erhvervet som led i selskabets aktietilbagekøb i 2024. Som konsekvens af kapitalnedsættelsen ændres vedtægternes pkt. 4.1 senest fire uger efter udløbet af fristen for kreditorers anmeldelse af krav, således at det herefter af pkt. 4.1 vil fremgå, at selskabets aktiekapital udgør DKK 42.758.932,60.
At bestyrelsen blev bemyndiget til indtil næste ordinære generalforsamling at lade selskabet tilbagekøbe aktier med en pålydende værdi af indtil 10 % af aktiekapitalen.
Efter generalforsamlingen konstituerede bestyrelsen sig med Niels B. Christiansen som formand og Niels Jacobsen som næstformand. Sisse Fjelsted Rasmussen fortsætter som formand for revisionsudvalget.
I henhold til paragraf 3.8.1 i Nasdaqs Nordic Main Market Rulebook for Issuers of Shares skal Demant hermed give følgende oplysninger som opfølgning på det aktiebaserede program for direktionen, der er en del af direktionens vederlag:
Beskrivelse af programmet
Et langsigtet incitamentsprogram i form af Restricted Stock Units (RSU’er), som efter optjening konverteres 1:1 til aktier i selskabet. Der henvises til selskabets vederlagspolitik for en detaljeret beskrivelse af programmet.
Optjeningsperiode
2025-2028, dvs. tre år
Performance-periode
2025, dvs. et år
Aktiekurs
DKK 263,50, dvs. gennemsnittet af kurserne noteret på Nasdaq i København de første fem handelsdage efter offentliggørelse af Demants årsrapport for 2024.
Samlet antal tildelte RSU’er
69.675
Programmets teoretiske markedsværdi
DKK 18.359.363 baseret på den aktiekurs, der anvendes til beregning af tildelingen. Beløbet repræsenterer den maksimale udbetaling, som justeres i forhold til performance-kriterierne.
Yderligere information:
Søren Nielsen, koncernchef og adm. direktør
Telefon +45 3917 7300
www.demant.com
Øvrige kontaktpersoner:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Henrik Axel Lynge Buchter, Manager of External Communications
Kontakter
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
Om Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Vedhæftninger
2025-04 Beslutninger på den ordinære generalforsamling.pdf
6.3.2025 16:08:36 CET | Demant A/S |
Decisions of general meeting
Company announcement no 2025-04
6 March 2025
Decisions of annual general meeting
Today, Demant A/S held its annual general meeting, which took place at the company’s premises, Kongebakken 9, 2765 Smørum, Denmark.
In his address, the Chair of the Board of Directors, Niels B. Christiansen, gave an account of the Group’s development in 2024. The report is available on www.demant.com. He said among other things:
“In 2024, the Group delivered organic growth of 2% and an operating result before special items of DKK 4.4 billion. This is in line with the expectations that we had to revise mid-year, where we also implemented cost-reducing measures to maintain profitability.
Demant is fully dedicated to promoting global hearing health so that we can help more people hear better. We are in a unique position to serve users and customers from the first screening, testing and fitting to ongoing personal treatment. As one of the world’s leading hearing health companies, we focus on creating growth and delivering attractive financial results based on a strong and sustainable business model. With our focus on innovation, artificial intelligence and service, we work intensively to ensure that we deliver on our long-term targets for growth and profitability, and also to make 2025 a good year for Demant.”
All proposals put forward by the Board of Directors were adopted by the general meeting, implying among others the following decisions:
The company’s Annual Report 2024 was approved, and the year’s profit, DKK 1,658 million, will be transferred to the company’s reserves.
Remuneration Report 2024 was approved.
The proposal for the Director’s fee to remain the same as in 2024 was adopted.
Niels B. Christiansen, Niels Jacobsen, Sisse Fjelsted Rasmussen and Kristian Villumsen were re-elected to the Board of Directors. In addition, Katrin Pucknat was elected new member of the Board of Directors.
The company’s auditors, PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (PwC), was re-elected. Furthermore, the proposal for PwC to be elected to provide the opinion on the limited assurance of sustainability reporting in the management report was adopted.
The company’s share capital will be reduced by nominally DKK 1,459,025.80, corresponding to the company’s holding of treasury shares as of 4 February 2025, less shares to cover share-based retention programmes for senior leadership and the Executive Board. The company’s holding of treasury shares was for the most part acquired as part of the company’s share buy-backs in 2024. As a result of the capital reduction, article 4.1 of the Articles of Association will be amended no later than four weeks after expiry of the deadline for the filing of claims by creditors, which means that upon expiry of this deadline, it will appear from article 4.1 that the company’s share capital is DKK 42,758,932.60.
Until the next ordinary general meeting, the Board was authorised to let the company buy back shares with a nominal value of up to 10% of the share capital.
After the general meeting, the Board of Directors elected Niels B. Christiansen Chair and Niels Jacobsen Vice Chair of the Board. Sisse Fjelsted Rasmussen continues as chair of the audit committee.
Pursuant to rule 3.8.1 in Nasdaq’s Nordic Main Market Rulebook for Issuers of Shares, Demant hereby provides the following information as follow-up on the Executive Board’s share-based programme, which is part of the Executive Board’s remuneration:
Description of the programme
A long-term incentive programme in the form of restricted stock units (RSUs), which will be converted into shares in the company on a 1:1 ratio at vesting. Please refer to the Remuneration Policy for a detailed description of the programme.
Vesting period
2025-2028, i.e. three years
Performance period
2025, i.e. one year
Share price used for grant calculation
DKK 263.50, i.e. the average share price quoted on Nasdaq Copenhagen of the first five trading days following the publication of Demant’s Annual Report 2024.
Total number of RSUs granted
69,675
Theoretical market value of the programme
DKK 18,359,363 based on the share price used for grant calculation and representing the maximum payout to be adjusted based on performance criteria.
Further information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Other contacts:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Henrik Axel Lynge Buchter, External Communication Manager
Contacts
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
About Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Attachments
2025-04 Decisions of annual general meeting.pdf
